Nexalin Technology Participates in Congressional Roundtable Focused on Emerging Virtual Therapeutic Options for Opioid Treatment
Nexalin Technology (Nasdaq: NXL) participated in a Congressional roundtable in North Carolina focused on virtual therapeutic options for opioid treatment. The event, hosted by the Breaking Barriers for Substance Use Recovery initiative, featured key healthcare and policy stakeholders. Congressman Dr. Greg Murphy, the only practicing physician in Congress, led discussions on deploying virtual-based opioid therapy models nationwide.
Nexalin's approach to virtual therapeutic solutions, pending FDA clearance, was highlighted as a promising tool against opioid addiction. The company's non-invasive neurostimulation technology aims to revolutionize addiction treatment, especially for veterans in rural communities. The roundtable emphasized establishing stronger practices within the VA and SAMHSA to encourage the adoption of virtual-based therapies, expanding the reach and impact of mental health care.
Nexalin Technology (Nasdaq: NXL) ha partecipato a un tavolo rotondo al Congresso in Carolina del Nord, incentrato sulle opzioni terapeutiche virtuali per il trattamento degli oppioidi. L'evento, ospitato dall'iniziativa Breaking Barriers for Substance Use Recovery, ha visto la partecipazione di principali attori del settore sanitario e delle politiche. Il Congressman Dr. Greg Murphy, unico medico praticante nel Congresso, ha guidato le discussioni sull'implementazione di modelli di terapia oppioide basati su virtualizzazione a livello nazionale.
In questo contesto, l'approccio di Nexalin alle soluzioni terapeutiche virtuali, in attesa dell'approvazione della FDA, è stato messo in evidenza come uno strumento promettente contro la dipendenza da oppioidi. La tecnologia di neurostimolazione non invasiva dell'azienda punta a rivoluzionare il trattamento della dipendenza, specialmente per i veterani nelle comunità rurali. Il tavolo rotondo ha enfatizzato la necessità di stabilire pratiche più solide all'interno del VA e del SAMHSA per incoraggiare l'adozione di terapie basate su virtualizzazione, ampliando la portata e l'impatto della salute mentale.
Nexalin Technology (Nasdaq: NXL) participó en una mesa redonda del Congreso en Carolina del Norte centrada en opciones terapéuticas virtuales para el tratamiento de opioides. El evento, organizado por la iniciativa Breaking Barriers for Substance Use Recovery, contó con la presencia de actores clave en el área de la salud y políticas. El congresista Dr. Greg Murphy, el único médico en ejercicio en el Congreso, lideró las discusiones sobre la implementación de modelos de terapia opioides basados en virtualización a nivel nacional.
El enfoque de Nexalin hacia las soluciones terapéuticas virtuales, a la espera de la aprobación de la FDA, fue destacado como una herramienta prometedora en la lucha contra la adicción a los opioides. La tecnología de neuroestimulacion no invasiva de la empresa pretende revolucionar el tratamiento de adicciones, especialmente para veteranos en comunidades rurales. La mesa redonda subrayó la importancia de establecer prácticas más sólidas dentro del VA y SAMHSA para fomentar la adopción de terapias basadas en virtualización, ampliando el alcance y el impacto de la atención de salud mental.
Nexalin Technology (Nasdaq: NXL)은 노스캐롤라이나에서 의회 원탁회의에 참여하여 오피오이드 치료를 위한 가상 치료 옵션에 대해 논의했습니다. Breaking Barriers for Substance Use Recovery 이니셔티브에서 주최한 이번 행사에는 주요 의료 및 정책 관계자들이 참석했습니다. 유일한 활동 의사인 그렉 머피 의원이 전 국가에 걸쳐 가상 기반 오피오이드 치료 모델을 배포하는 것에 대한 논의를 이끌었습니다.
Nexalin의 가상 치료 솔루션에 대한 접근법은 FDA 승인을 기다리고 있으며, 오피오이드 중독에 대한 유망한 도구로 강조되었습니다. 회사의 비침습적 신경자극 기술은 특히 농촌 지역의 재향군인들의 중독 치료를 혁신하는 것을 목표로 하고 있습니다. 원탁회의는 VA 및 SAMHSA 내에서 더 강력한 관행을 확립하여 가상 기반 치료법의 채택을 장려하는 것이 정신 건강 관리의 범위와 영향을 확대하는 데 중요함을 강조했습니다.
Nexalin Technology (Nasdaq: NXL) a participé à une table ronde au Congrès en Caroline du Nord, axée sur les options thérapeutiques virtuelles pour le traitement des opiacés. L'événement, organisé par l'initiative Breaking Barriers for Substance Use Recovery, a rassemblé des acteurs clés du secteur de la santé et des politiques. Le Congressman Dr. Greg Murphy, le seul médecin en exercice au Congrès, a dirigé les discussions sur la mise en œuvre de modèles de thérapie opiacée basés sur la virtualité à l'échelle nationale.
L'approche de Nexalin en matière de solutions thérapeutiques virtuelles, en attente d'approbation de la FDA, a été mise en avant comme un outil prometteur contre la dépendance aux opiacés. La technologie de neurostimulation non invasive de l'entreprise vise à révolutionner le traitement des addictions, en particulier pour les anciens combattants des communautés rurales. La table ronde a souligné la nécessité d'établir des pratiques plus solides au sein du VA et du SAMHSA pour encourager l'adoption de thérapies virtuelles, élargissant ainsi la portée et l'impact des soins de santé mentale.
Nexalin Technology (Nasdaq: NXL) nahm an einem Runder Tisch im Kongress in North Carolina teil, der sich auf virtuelle therapeutische Möglichkeiten zur Behandlung von Opioiden konzentrierte. Die Veranstaltung, die von der Initiative Breaking Barriers for Substance Use Recovery ausgerichtet wurde, brachte wichtige Akteure aus dem Gesundheits- und Politiksektor zusammen. Congressman Dr. Greg Murphy, der einzige praktizierende Arzt im Kongress, leitete die Diskussionen über die bundesweite Implementierung virtueller Opioidtherapiemodelle.
Der Ansatz von Nexalin für virtuelle therapeutische Lösungen, der auf die Genehmigung durch die FDA wartet, wurde als vielversprechendes Werkzeug im Kampf gegen die Opioidabhängigkeit hervorgehoben. Die nicht-invasive Neurostimulations-Technologie des Unternehmens zielt darauf ab, die Behandlung von Abhängigkeit zu revolutionieren, insbesondere für Veterans in ländlichen Gemeinden. Der Runden Tisch betonte die Notwendigkeit, stärkere Praktiken innerhalb des VA und SAMHSA zu etablieren, um die Annahme virtueller Therapien zu fördern und die Reichweite und den Einfluss der psychischen Gesundheitsversorgung zu erweitern.
- Participation in high-profile Congressional roundtable enhances Nexalin's visibility and potential influence in opioid treatment policy
- Nexalin's virtual therapeutic solutions recognized as a promising tool in fighting opioid addiction
- Potential for expanding Nexalin's market reach through virtual care solutions, especially in rural areas
- Alignment with government initiatives could lead to increased adoption of Nexalin's technology in VA and SAMHSA programs
- Nexalin's technology still pending FDA clearance, indicating potential regulatory hurdles
- No concrete financial or business metrics provided to assess immediate impact on company performance
Meeting showcases the potential role of Nexalin's neurostimulation technology in revolutionizing opioid treatment through virtual care solutions
HOUSTON, TX, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) announced its participation in a high-profile Congressional roundtable in North Carolina, focused on emerging virtual therapeutic options for opioid treatment. The event was hosted by the Breaking Barriers for Substance Use Recovery initiative and featured key stakeholders from across the healthcare and policy spectrum.
The roundtable, held with Dr. Greg Murphy, U.S. Congressman representing North Carolina's 3rd District, centered on the deployment of virtual-based opioid therapy models across the country. Dr. Murphy, Congress’ only actively practicing physician, serves on the Health Subcommittee of the Veterans Affairs Committee and is a strong advocate for innovative healthcare solutions, particularly those aimed at addressing the opioid crisis.
The invitation-only roundtable brought together thought leaders and innovators to discuss the potential of virtual therapies to overcome the stigma and geographic barriers often associated with traditional in-clinic treatment options. Nexalin’s approach to virtual therapeutic solutions, which is expected to play a significant role upon FDA clearance, was highlighted as a promising tool in the fight against opioid addiction.
“Nexalin is honored to participate in this crucial dialogue and to work alongside visionary leaders in the fight against addiction like Congressman Murphy, who has worked tirelessly to address challenges at the VA in service of our veterans,” said Mark White, CEO of Nexalin Technology. “Our mission is to provide effective, accessible treatment options that can reach those in need, regardless of their location. We believe that virtual therapeutic models, combined with our non-invasive neurostimulation technology, have the potential to revolutionize the way opioid addiction is treated across the nation, especially among veterans in rural communities. This meeting continues to build on the success of our Nexalin America division, which is aimed at expanding Nexalin’s efforts within the U.S. Government areas of interest.”
During the discussions, emphasis was placed on establishing stronger practices within the Department of Veterans Affairs (VA) and the Substance Abuse and Mental Health Services Administration (SAMHSA) to encourage the adoption of virtual-based therapies. These therapies, including Nexalin’s cutting-edge neurostimulation technology, aim to provide effective treatment options that can be accessed remotely, expanding the reach and impact of mental health care.
About Nexalin Technology, Inc.
Nexalin designs and develops innovative neurostimulation products to uniquely help combat the ongoing global mental health epidemic. All of Nexalin’s products are believed to be non-invasive and undetectable to the human body and are developed to provide relief to those afflicted with mental health issues. Nexalin utilizes bioelectronic medical technology to treat mental health issues. Nexalin believes its neurostimulation medical devices can penetrate structures deep in the mid-brain that are associated with mental health disorders. Nexalin believes the deeper-penetrating waveform in its next-generation devices will generate enhanced patient response without any adverse side effects. The Nexalin Gen-2 15 milliamp neurostimulation device has been approved in China, Brazil, and Oman. Additional information about the Company is available at: https://nexalin.com/.
FORWARD-LOOKING STATEMENTS
This press release contains statements that constitute “forward-looking statements,” These statements relate to future events or Nexalin’s future financial performance. Any statements that refer to expectations, projections or other characterizations of future events or circumstances or that are not statements of historical fact (including without limitation statements to the effect that Nexalin or its management “believes”, “expects”, “anticipates”, “plans”, “intends” and similar expressions) should be considered forward looking statements that involve risks and uncertainties which could cause actual events or Nexalin’s actual results to differ materially from those indicated by the forward-looking statements. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's Report on Form 10-K for the year ended December 31, 2023 and other filings as filed with the Securities and Exchange Commission. Copies of such filings are available on the SEC’s website, www.sec.gov. Such forward-looking statements are made as of the date hereof and may become outdated over time. Such forward-looking statements are made as of the date hereof and may become outdated over time. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
Contact:
Crescendo Communications, LLC
Tel: (212) 671-1020
Email: NXL@crescendo-ir.com
FAQ
What was the focus of the Congressional roundtable Nexalin Technology (NXL) participated in?
Who hosted the roundtable event that Nexalin Technology (NXL) attended?
How does Nexalin Technology (NXL) plan to contribute to opioid addiction treatment?
What potential impact could Nexalin's (NXL) participation in this roundtable have on its business?
